



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 6413**
Noboru TSUCHIMORI et al. : Attorney Docket No. 2007_0561
Serial No. 10/511,112 : Group Art Unit 1612
Filed October 21, 2004 : Examiner Carlic K. Huynh
USE OF COMPOUNDS HAVING CCR :
ANTAGONISM : **Mail Stop: Amendment**

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

This is responsive to the PTO Communication dated February 14, 2008.

The Communication states that the Reply filed November 27, 2007 is not fully responsive to the prior Office Action because an election of species was omitted.

Applicants elect as a single compound species the following compound which is recited in claim 3:

1-acetyl-N-(3-{4-[4-(aminocarbonyl)benzyl]-1-piperidinyl}propyl)-N-(3-chloro-4-methylphenyl)-4-piperidinecarboxamide.

Favorable action on the merits is respectfully solicited.

Respectfully submitted,

Noboru TSUCHIMORI et al.

By: Warren M. Cheek
Warren M. Cheek
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 11, 2008



339

a cyclic ring group together with the adjacent phosphorus atom, (5) an amidino group which may be substituted or (6) a guanidino group which may be substituted, or a salt thereof.

- 5 3. The agent for the prevention or treatment according to claim 1 or 2, wherein the compound having a CCR antagonistic effect or a salt thereof is N-(3,4-dichlorophenyl)-1-(methylsulfonyl)-N-{3-[4-((4-
10 [(methylsulfonyl)-amino]phenyl)sulfonyl)-1-piperidinyl]propyl}-4-piperidinecarboxamide, N-(3-chlorophenyl)-1-(methylsulfonyl)-N-(3-{4-[4-(methylsulfonyl)benzyl]-1-piperidinyl}propyl)-4-piperidinecarboxamide, N-(3-{4-[4-(aminocarbonyl)benzyl]-1-piperidinyl}propyl)-N-(3,4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide, 1-acetyl-N-(3-
15 {4-[4-(aminocarbonyl)benzyl]-1-piperidinyl}propyl)-N-(3-
chloro-4-methylphenyl)-4-piperidinecarboxamide, N-(3,4-dichlorophenyl)-N-(3-{4-[4-(ethylsulfonyl)benzyl]-1-piperidinyl}propyl)-1-(methylsulfonyl)-4-piperidinecarboxamide, N-(3,4-dichlorophenyl)-N-(3-{4-[4-(isopropylsulfonyl)benzyl]-1-piperidinyl}propyl)-1-(methylsulfonyl)-4-piperidinecarboxamide, N-(3-chlorophenyl)-N-(3-{4-[4-(isopropylsulfonyl)benzyl]-1-piperidinyl}propyl)-1-(methylsulfonyl)-4-piperidinecarboxamide, N-(3-chlorophenyl)-N-(3-{4-[4-
- 20 piperidinecarboxamide, N-(3,4-dichlorophenyl)-N-(3-{4-[4-(isopropylsulfonyl)benzyl]-1-piperidinyl}propyl)-1-(methylsulfonyl)-4-piperidinecarboxamide, N-(3-chlorophenyl)-N-(3-{4-[4-
- 25 piperidinecarboxamide, N-(3-chlorophenyl)-N-(3-{4-[4-